The Effect of Curcumin Against Colistin-induced Nephrotoxicity
Acute Kidney Injury, Drug-Induced Nephropathy
About this trial
This is an interventional prevention trial for Acute Kidney Injury
Eligibility Criteria
Inclusion Criteria: All critically ill adult patients (18-65 years old) who are infected by MDR Gram-negative bacteria and require intravenous colistin therapy Exclusion Criteria: Patients receiving intravenous colistin therapy for < 72 hours. Patients receiving renal replacement therapy (RRT). Patients with diseases that may contribute to renal impairment such as systemic lupus erythematosus, acute myocardial infarction, cancer, HIV infection, glucose-6-phosphate-dehydrogenase deficiency, or urinary tract stone. Pregnancy or breastfeeding. Known allergy to the study medications. Patients with chronic kidney diseases (creatinine clearance < 60 mg/dL). Elevated total liver enzymes (AST, and ALT) three times above the upper limit of normal. Patients with acute decompensated heart failure signs and symptoms requiring intravenous loop diuretics and/or intravenous inotropes and/or ACE inhibitors. Uncontrolled diabetes (Glycosylated hemoglobin (Hb A1C) >8%). Hypotensive patients defined as decrease in blood pressure less than 90/60 mm Hg. Recent use of vitamins with antioxidant properties such as beta carotene, vitamin E, vitamin C, selenium, or N-acetylcysteine or any other medications known to have nephroprotective activities. Patients receiving other nephrotoxic drugs at enrollment (e.g., aminoglycosides, vancomycin, or amphotericin B) or administration of contrast medium within 7 days.
Sites / Locations
- Cairo University HospitalsRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Group 1
Group 2
patients in this group will receive loading dose of colistin intravenously of 9 MIU followed by maintenance doses of 4.5 MIU given every 12 hours.
patients in this group will receive loading dose of colistin intravenously of 9 MIU followed by maintenance doses of 4.5 MIU given every 12 hours and curcumin will be administered as orally or through nasogastric tube at a dose of 2 capsules every 6 hours (1 gm/6 hour)